Robert “Bert” Hazlett

Robert (Bert) Hazlett is a Managing Director and Biotechnology Equity Research Analyst at BTIG. He provides coverage of companies in several therapeutic categories in the biotechnology sector, with a focus on CNS, oncology and anti-infective companies. Prior to BTIG, Mr. Hazlett was a Biotechnology Equity Research Analyst at Ladenburg Thalmann & Co., and a Senior Research Analyst at Roth Capital Partners. Previously, he accumulated over a decade of experience as a Senior Analyst covering both the large capitalization and emerging pharmaceuticals sectors while at BMO Capital Markets, SunTrust Robinson Humphrey, Lehman Brothers and UBS. Mr. Hazlett also served as a consultant for several emerging biotechnology companies throughout his career. In 2015, he was named a top stock picker in the biotechnology sector by Thomson Reuters’ StarMine Analyst Awards. Mr. Hazlett began his career as a Portfolio Manager in the Money Markets Division at the U.S. Trust Company of New York. He earned a BA from Yale University, and an MBA from Columbia University.